Navigation Links
ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
Date:12/5/2007

- Pre-IND meeting with FDA scheduled for January for lead antibody program

-

TORONTO, Dec. 5 /PRNewswire-FirstCall/ - ARIUS Research Inc. (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that it has entered into a manufacturing supply and technology transfer agreement for its CD44 Cancer Stem Cell antibody with Avid Bioservices, a company providing cGMP manufacturing services for the biotechnology and biopharmaceutical industries. Avid has begun manufacturing a supply of the drug for human clinical trials which ARIUS plans to initiate in 2008. ARIUS also announced it has scheduled a pre-IND meeting with the FDA that will take place in January.

"The initiation of manufacturing and the scheduling of our pre-IND meeting with the FDA in January reflect the significant progress we have made with our CD44 Cancer Stem Cell program," said Dr. David Young, President and Chief Executive Officer of ARIUS. "Avid has proven expertise in the scale-up and manufacture of clinical and commercial grade antibodies and will provide us with a supply of our CD44 targeting drug to initiate human clinical trials in 2008, subject to the clearance of our IND by the FDA."

"This new manufacturing agreement is the result of the solid working relationship we have developed with the ARIUS team," said F. David King, Vice President, Business Development of Avid. "Our goal is to form strategic partnerships with innovative life sciences companies like ARIUS, serving as a premier service provider by seamlessly integrating our experience and capabilities with our clients' needs."

ARIUS is advancing the formal pre-clinical toxicology program for its lead CD44 Cancer Stem Cell program, an anti-cancer antibody targeting a novel epitope of CD44 found in breast, colon, and prostate cancers. Pre-clinical data from a dose-ranging pilot toxicology study in non-human prima
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 About POCT ... performed outside a clinical laboratory. It helps in ... appropriate treatments and medication. POCT is gaining popularity ... lifestyle diseases such as diabetes, heart disease, and ... devices are standardized to minimize errors during the ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... an exclusive license for technology developed by the ... expression in plants, including for applications in production of ... The technology was developed under the direction of ... Kultevat and former president of the Danforth Plant Science ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 2
... KBI Biopharma, Inc. (KBI) announced today that it ... with Crucell,s PER.C6(R) human cell line platform, pursuant to ... 6, 2009. Under that agreement, KBI joins the Vendor ... for licensees of the PER.C6(R) cell lines. , ...
... International Products Corporation,s ( http://www.ipcol.com ) ... membrane compatibility and performance studies using a versatile ... any type of membrane media, from UF to RO, and ... "Our goal is to be able to recommend the most ...
... Release Highlights, - Melogliptin continues to demonstrate potential to ... low incidence of, hypoglycemia and neutral effect on ... by end 2009, - IND approved by USFDA, ... Indian company to have a truly global innovative drug for ...
Cached Biology Technology:KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R) 2International Products Corp.'s Lab Offers Filter Membrane Compatibility and Studies 2Glenmark's Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials 2
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... fairness did not evolve for the sake of fairness ... of continued cooperation, so say Frans de Waal, PhD, ... about inequity aversion (IA), which is defined as a ... in Science . , Their conclusion comes ... to address their hypothesis that it is the evolution ...
(Date:9/18/2014)... A new GSA Bulletin study uses ... Rio Puerco and Chaco Wash in northern New Mexico, ... salt cedar and willow, investigators were able to precisely ... They then combined this data with aerial imagery, LiDAR, ... of these arroyos. , Arroyos are deep, oversized channels ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... as to how HIV evades the human immune system ... The findings suggest some HIV vaccines may have failed ... patient's own immune system is programmed to destroy. , ... which recognize and latch onto the HIV protein gp41, ...
... Africa, where days of heavy rains and flooding have led ... are reporting an unprecedented rise in Somalia's Shabelle River and ... centre of the country, the United Nations said today. , ... Affairs (OCHA), reports yesterday from Belet Weyne, close to the ...
... to recover in adolescent females once they stop using ... a study funded by the National Institute of Child ... Health. , Previous studies had shown that women who ... a loss of bone mineral density during the time ...
Cached Biology News:New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines 2New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines 3Bone Density Recovers After Teens Stop Injected Contraceptive 2Bone Density Recovers After Teens Stop Injected Contraceptive 3
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
... for calibrating single-channel and multi-channel pipettes. ,Thanks ... carrying case, the MCP1-S is ideal for ... on-site at the users premises. The unit ... individual channels are tested automatically. Multi-channel pipettes ...
... ChIP-on-chip Microarray is specifically designed for ... DNA binding proteins by pairing chromatin ... This set delivers robust hybridization and ... binding events and fewer false positives. ...
... Genome ChIP-on-chip Microarray is specifically designed ... cerevisiae) DNA binding proteins by pairing ... microarrays. This set delivers robust hybridization ... true binding events and fewer false ...
Biology Products: